Oncotarget

Research Perspectives:

Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect

Pedro Sousa-Victor, Laura García-Prat and Pura Muñoz-Cánoves _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:23052-23054. https://doi.org/10.18632/oncotarget.5563

Metrics: PDF 1841 views  |   HTML 2282 views  |   ?  


Abstract

Pedro Sousa-Victor1,2, Laura García-Prat2 and Pura Muñoz-Cánoves2

1 Buck Institute for Research on Aging, Novato, CA, USA

2 Cell Biology Group, Department of Experimental and Health Sciences, Pompeu Fabra University (UPF), CIBER on Neurodegenerative Diseases (CIBERNED), and ICREA, Barcelona, Spain

Correspondence to:

Pura Muñoz-Cánoves, email:

Keywords: senescence, aging, quiescence, geroconversion, mTOR

Received: June 23, 2015 Accepted: August 19, 2015 Published: September 10, 2015

Abstract

Over the past decade, our understanding of the molecular and cellular mechanisms presiding over cellular and tissue decline with aging has greatly advanced. Classical hallmarks of aging cell include increasing levels of reactive oxygen species, DNA damage and senescence entry, which disrupt tissue architecture and function. Tissue dysfunction with aging has been shown to correlate with a cellular switch from a G0 reversible quiescence state into a G0 irreversible senescence state (geroconversion), causing a permanent proliferative block. The TOR (target of rapamycin) kinase has been shown to promote geroconversion. Rapamycin and other rapalogs specifically suppress activity of the mammalian TOR (mTOR) complex 1 (mTORC1) -but not mTOR complex 2 (mTORC2)- and decrease senescence entry, thus preserving proliferative potential. In this perspective, we briefly comment recent progress of Leontieva and colleagues showing a new class of non-rapalog drugs that target simultaneously mTORC1 and mTORC2 and prevent geroconversion in a more efficient way than rapamycin. Its potential future use as rejuvenating, anti-aging therapeutics is therefore proposed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5563